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INTRODUCTION 
The concept of CRC screening has transformed over the past few decades, with the 
realization that the benefit is less from the detection of early curable-stage cancer, than it is from 
prevention of cancer via detection and elimination of premalignant lesions. The amenability to 
primary prevention is a fundamental characteristic of CRC which distinguishes it from other 
“screenable” cancers, where the focus is generally on secondary prevention via detection of 
early stage malignancy1. This paradigm originated in 1965 with Gilbertsen2, who postulated that 
CRC could be prevented by polypectomy, and was later supported by the biologic framework of 
the Fearon-Vogelstein adenoma-carcinoma sequence3. It is now accepted that most CRCs 
develop within precursor adenomatous or serrated polyps, and that interruption of the polyp-to-
cancer sequence prevents the development of CRC. The effect of this interruption on patient 
outcomes has been the subject of multiple investigations. Several observational studies have 
reported reduced CRC incidence and mortality after colonoscopy 4-14. However, patients in 
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these studies were heterogeneous, including those with no findings and those with various 
precursor polyp types and numbers. This affects the interpretability of the findings, because it is 
known from several “negative colonoscopy” studies15-19 that patients without polyps are a lower-
risk group among the larger average-risk population. It is important to make a distinction 
between these groups, because prevention of CRC by endoscopic procedures is not due to the 
identification of persons without polyps, but rather to the detection and complete resection of 
polyps in patients with colorectal neoplasia. In other words, the main effector of CRC prevention 
is polypectomy.     
   There are presently no data from randomized controlled trials (RCT) to determine the 
effect of polypectomy on CRC incidence and mortality. Isolating the effect of polypectomy would 
require a randomized design with a control group where polyps are left in situ without resection, 
which is not a reasonable nor ethical consideration. There are 4 large ongoing RCTs20-23 in 
Europe and the U.S. comparing colonoscopy to fecal immunochemical testing for CRC 
screening that could clarify the impact of polypectomy, but their results will not be available for 
years. Despite the lack of RCT-level data, the effectiveness of polypectomy to prevent CRC is 
indisputable. Proof of this assertion is derived from several lines of evidence, including 
epidemiologic data, RCTs of fecal occult blood tests (FOBT) and flexible sigmoidoscopy, and 
from observational colonoscopy studies.    
Epidemiologic observations 
Colorectal Cancer (CRC) is a worldwide scourge with globally increasing burden. 
However, from the epidemiologic standpoint, the United States has been an exception, with 
steadily decreasing incidence rates since the 1980s24, and long-term projections predicting 
declines through 203025. There has been debate regarding the relative contribution of risk factor 
modification to the US CRC epidemiological trends, because the declines began prior to the 
mass screening era26. However, it is impossible not to attribute a majority of the benefit to 
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widespread awareness and compliance with screening, and resultant removal of precancerous 
polyps: In the US, CRC declines have been most noticeable in those 65 years and older, and 
have accelerated for proximal colon cancer in the past decade24, an observation likely driven by 
increased use of colonoscopy and polypectomy. The more recently noted increases in CRC 
incidence in persons < 50 years old27, who are not routinely screened for CRC, provides an 
indirect argument that polypectomy is largely responsible for CRC decreases in screening-
eligible age groups. That more colonoscopy and polypectomy could alter CRC epidemiology at 
the population level is supported by recent evidence from Germany, where CRC incidence and 
mortality have begun to decrease 10 years after colonoscopy was added to the German 
national cancer screening program28.   
    
Evidence from FOBT studies 
 Randomized controlled trials have consistently shown that screening with FOBT is 
associated with reductions in CRC mortality ranging from 15% to 33%29-33. The FOBT is 
primarily a test for the detection of CRC, and it can be argued that the beneficial effect of FOBT-
based screening strategies is derived from detection of early-stage cancers. However, studies 
reporting the long-term outcomes of patients after FOBT screening suggest that colonoscopy 
with polypectomy is in fact a major contributor to the observed reductions in CRC mortality. The 
Minnesota Colon Cancer Control Study34 randomized 46,551 participants to annual or biennial 
FOBT screening or usual care. Through 30 years of follow-up, screening was associated with 
lower CRC mortality with annual (RR 0.68; 0.56-0.82) and biennial screening (RR 0.78, 0.65-
0.93) compared to usual care, while all-cause mortality was not significantly different. 
Importantly, the CRC mortality reduction of 32% at 30 years was sustained throughout the 
observation period, and similar to estimates at earlier time points. If early detection of CRC was 
the primary mechanism by which FOBT screening leads to decreased CRC mortality, the 
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benefit would be most apparent during the first few years of follow-up after removal of CRC 
cases from the cohort, then deteriorate over time. The lack of such an observation strongly 
suggests that in patients with positive FOBT, colonoscopy with polypectomy and subsequent 
colonoscopic surveillance are responsible for the sustained long-term reduction in CRC 
mortality. An earlier analysis of the Minnesota FOBT cohort attributed a 20% reduction in CRC 
incidence after 18 years to colonoscopy with resection of polyps35. 
A more modest reduction in CRC mortality of 13% was reported after 20 years of follow-
up of patients in the Nottingham FOBT RCT, and no reduction in CRC incidence despite the 
removal of over 600 large adenomas in the intervention arm36. It is important to note, though, 
that the Nottingham and Minnesota trials differed in key aspects, notably the use of non-
rehydrated FOBT leading to lower positivity and subsequent colonoscopy rates, and lower 
participant compliance rates in the Nottingham RCT.  
Evidence from sigmoidoscopy studies 
The results of sigmoidoscopy-based screening have been extrapolated to colonoscopy 
because they are both structural examinations of the colon and utilize the same endoscopic 
technology. Four large sigmoidoscopy RCTs have reported significant reductions in CRC 
incidence and mortality (Table 1) and meta-analyses have reported overall CRC mortality 
reductions of about 28%37, 38. 
The UK RCT39 assessed over 170,000 participants who were assigned to 
sigmoidoscopy or control groups, and of which about 5% were referred to colonoscopy for large, 
histologically advanced, or multiple adenomas. In intention-to-treat analyses, after 11 years of 
follow-up, CRC incidence was reduced by 23% (hazard ratio 0.77, 95% CI 0.70-0.84) and 
mortality by 31% (0.69, 0.59-0.82) in the sigmoidoscopy group. After median follow-up of 17 
years, CRC incidence and mortality reductions were 26% and 30%, respectively40. The 
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Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer RCT41 randomized 154,900 
participants to screening sigmoidoscopy (repeated at 3 or 5 years) or to usual care. After a 
median of 12 years, CRC incidence was reduced by 21%, and CRC mortality by 26%. It is, 
however, difficult to isolate the effect of polypectomy performed in the sigmoidoscopy RCTs and 
separate it from that of subsequent colonoscopies, because these employed different polyp 
resection policies at the time of sigmoidoscopy, different colonoscopy referral strategies, and 
colonoscopy utilization and contamination varied between studies. For example, in the PLCO 
trial, patients with polyps at sigmoidoscopy were advised to undergo colonoscopy with about 
80% compliance rate; conversely, the contamination rates in the usual care arm were 26% for 
flexible sigmoidoscopy and 34% for colonoscopy41.  A meta-analysis showed that colonoscopy 
was associated with a 40% to 60% lower risk of incident CRC and death from CRC than 
sigmoidoscopy, which was statistically significant only for deaths due to proximal cancer42. 
 
Evidence from colonoscopy studies 
  The first colonoscopy study to demonstrate unequivocally that polypectomy prevents 
CRC was the National Polyp Study (NPS)43. The NPS cohort included 1418 patients who 
underwent colonoscopy with resection of at least one adenoma, and followed for a mean of 6 
years. Five asymptomatic CRCs were detected during surveillance, corresponding to a 76% 
reduction in CRC compared with a Surveillance, Epidemiology, and End Results (SEER) 
reference group, and no CRC deaths occurred. The long-term NPS follow up study44 provides 
compelling proof of the effectiveness of polypectomy to prevent CRC: The cohort included 2602 
patients with adenomas (including the 1418 who were randomized in the original NPS 
assessing surveillance intervals after colonoscopy) followed for up to 23 years after 
polypectomy. Compared to a SEER control population, CRC mortality was reduced by 53% 
(95% CI 20%-74%), and the reduction for the first 10 years was similar to after 10 years of 
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follow-up. In addition, CRC mortality was similar among for adenoma patients compared to an 
internal control group with nonadenomatous polyps for the first 10 years after polypectomy 
(relative risk, 1.2; 95% CI, 0.1 to 10.6).  
An Italian observational prospective cohort study45 of 1693 patients who underwent 
colonoscopic polypectomy of adenomas ≥ 5 mm reported a 66% (95% CI 37%-77%) CRC 
incidence reduction, compared to the general Italian population. Adenoma cohort studies 
published after the NPS and Italian study showed far less impressive reductions in CRC 
incidence after polypectomy. The Funen Adenoma Follow-up Study46, which assessed 
surveillance intervals in patients with adenomas, reported significant reductions in CRC 
incidence and mortality for up to 24 years after adenoma resection: Compared to the Danish 
population, CRC incidence RR was 0.65 (95% CI 0.43–0.95) and CRC death RR was 0.12 
(95% CI 0.03–0.36). The Wheat Bran Fiber Trial47 and Polyp Prevention Trial48 assessed the 
effect of fiber to prevent adenoma recurrence after polypectomy, and both reported much higher 
CRC incidence rates compared to the NPS (2.2 versus 0.6 per 1000 patient-years).  Another 
study49 combined data from 3 adenoma chemoprevention RCTs which assessed the effect of 
calcium, folic acid, antioxidants, and aspirin on recurrence rates of colorectal adenomas after 
colonoscopy and polypectomy. The overall incidence of CRC was 1.74 (95% CI, 1.05–2.72) per 
1000 person-years of follow-up, compared to 0.6 and 0.4 in the NPS and Italian studies, 
respectively, and was not significantly different from expected incidence based on SEER data 
(standardized incidence ratio for CRC, 0.98; 95% CI, 0.63–1.54).  
The potential reasons for these discrepant findings are many50. First, the NPS included a 
small number of experienced endoscopists, and there was significant focus on ensuring 
complete adenoma clearance prior to enrollment: patients with adenomas larger than 3 cm were 
excluded, and about 13% of the cohort underwent more than one baseline colonoscopy. 
Second, there were important methodological differences, including duration of follow up, 
7 
 
distinction between prevalent and incident CRC cases, the characteristics and CRC risk of the 
groups chosen for comparison, and frequency of surveillance colonoscopies after the index 
procedure. Finally, the quality of colonoscopy, notably neoplasia detection and completeness of 
polypectomy, were likely a contributing factor. These studies were conducted in an era which 
preceded the recognition of the importance of colonoscopy quality and its impact on the risk of 
post-colonoscopy CRC51, 52. While information about endoscopists’ adenoma detection rates 
and completeness of polypectomy is not available, the characteristics of the incident cancers 
reported in these studies strongly suggest that colonoscopy quality is a major factor, as most 
would qualify as interval or post-colonoscopy CRC based on current definitions. For example, in 
the NPS, 3 of 5 incident cancers were detected 3 years after the index procedure, all 9 cancers 
in the Wheat Bran Fiber Trial were found within 3 years, whereas 10 of 13 CRC in the Polyp 
Prevention trial were judged to be due to missed cancer, incomplete polypectomy, or 
inadequate biopsy.  In the combined chemoprevention trial, 17 of 19 CRC were detected within 
4 years of the baseline colonoscopy and most were in the proximal colon.  
 The central importance of polypectomy quality is not a theoretical one. In the landmark 
Complete Adenoma Resection (CARE) study53, investigators biopsied the margins of 346 
polypectomy sites, and found an incomplete resection rate (IRR) of 10.1% (95% CI 6.9%-
13.3%), and ranged from 6.5% to 22.7% among endoscopists. Larger polyps were more likely to 
be incompletely resected than smaller polyps (17.3% vs. 6.8%). The IRR of 10%, alarming 
enough by itself, is likely an underestimate of the true prevalence of this problem in clinical 
practice, because study endoscopists were aware that they participating in research and that 
their performance was being scrutinized. It is currently estimated that between 10% and 25% of 
PCCRC are due to incomplete polypectomy. 
More recent studies have further highlighted the effect of polypectomy on CRC 
prevention, and the importance of continued surveillance in select higher-risk patients. An 
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administrative claims-based study from Ontario54 assessed whether characteristics of 
endoscopists are associated with risk of PCCRC in 14,064 patients. In multivariate analyses, 
patients with proximal cancers undergoing colonoscopy by endoscopists who performed 
polypectomies at high rates had a lower risk of PCCRC. Compared to < 10% polypectomy rate 
reference, the OR was 0.52 if the polypectomy rate was 25% to 29%, and 0.61 for rates > 30%. 
Conversely, distal CRC was not associated with polypectomy rate. A large prospective study14 
examined the association of colonoscopy and sigmoidoscopy with CRC incidence and mortality 
among 88,902 participants in the Nurses' Health Study and the Health Professionals Follow-up 
Study. In follow-up of over 22 years, compared to patients who had not undergone lower 
endoscopy, the multivariate hazard ratios for CRC among participants were 0.57 (95% CI, 0.45-
0.72) after resection of adenomatous polyps, 0.60 (95% CI, 0.53-0.68) after negative 
sigmoidoscopy, and 0.44 (95% CI, 0.38-0.52) after negative colonoscopy. Polypectomy was 
associated with reduced distal CRC incidence (HR 0.40; 95% CI, 0.27-0.59), although proximal 
colon cancer incidence was not significantly different. One possible advantage of this study over 
the NPS is that the polypectomy and control groups were derived from the same background 
population, allowing more direct comparison of CRC incidence rates after polypectomy and 
adjustment for confounding factors.   
 A French population-based cohort study55 investigated CRC incidence in 5779 patients 
with adenomas, followed for a median of 7.7 years. Compared with the general French 
population, 87 CRC were diagnosed versus 69 expected, for a standardized incidence ratio 
(SIR) of 1.26 (95% CI 1.01-1.56). CRC risk depended on the features of the index adenoma and 
whether surveillance colonoscopy occurred: The SIR was 2.23 (95% CI 1.67-2.92) for advanced 
adenomas compared to 0.68 (95% CI 0.44-0.99) for non-advanced adenomas. For advanced 
adenomas, the SIR decreased to 1.10 (95% CI 0.62-1.82) for patients who underwent 
colonoscopic surveillance, but increased to 4.26 (95% CI 2.89-6.04) for those who did not.  
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A population-based study from Norway56 followed a cohort of 40,826 patients who 
underwent resection of colorectal adenomas between 1993 and 2007, and followed for a 
median of 7.7 years. Compared to the general Norwegian population, 383 CRC deaths were 
recorded (398 expected) for a standardized mortality ratio of 0.96 (95% CI: 0.87-1.06). CRC 
mortality was increased in high-risk adenoma patients (SMR, 1.16; 95% CI, 1.02- 1.31), and 
decreased among those with low-risk adenomas (SMR, 0.75; 95% CI, 0.63-0.88).  
A study57 based on a Northern Ireland polyp registry reported a nearly 3-fold increased 
CRC risk among 6,972 adenoma patients, and the excess risk was associated with inadequate 
colon clearance and follow up after polypectomy.  
Additional insight can be gained from follow-up of the subgroup of nearly 16,000 
participants who underwent colonoscopy following abnormal findings on sigmoidoscopy58.  
When stratified according to adenoma findings at colonoscopy, and after a median of 13 years 
of follow-up, CRC incidence rates (per 10 000 person-years) were 20.0 (95% CI, 15.3-24.7) for 
advanced adenoma, 9.1 (95% CI, 6.7-11.5) for nonadvanced adenoma, and 7.5 (95% CI, 5.8-
9.7; n = 71) for no adenoma. Participants with advanced adenoma were about 2.5 times more 
likely to develop or die from CRC compared with participants with no adenoma. There were no 
significant differences in CRC incidence and mortality between participants with nonadvanced 
adenoma compared with no adenoma.   
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